Non Small Cell Lung Cancer (NSCLC)

Stage I-III, Resectable

Standard Risk

Scheduled for Resection

Tumor < 4 cm. No Clinical Nodes

LUN0101
Phase III Chemotherapy +/-Pembrolizumab in Necadjuvant/Adjuvant Tx Resectable Stage IIB / IIIA NSCLC
PI: Wakelee Pending

LUN0099
Phase III Panitumumab IRDye800 Optical Imaging Agent to Detect Lung Cancer During Surgery
PI: Lui Stanford

LUN0076
Phase III Atezolizumab (Anti-PD-L1 Antibody) vs Best Supportive Care in Non Small Cell Lung Cancer
PI: Wakelee Genentech

ALK Mutation

ECOGE4512
Phase III Crizotinib vs Observation in NSCLC w/ Anaplastic Lymphoma Kinase (ALK) Fusion Protein Tumors
PI: Wakelee ECOG-ACRIN

EGFR Mutation

ECOGA081105
Phase III Erlotinib or Placebo in Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC
PI: Wakelee ECOG-ACRIN

High Risk

Peripheral Tumors

LUN0048
Phase II trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (SABR)
PI: Diehn Stanford